https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
A randomized double-blind crossover study on 8 healthy males showed that UniORV achieved a 1.4-fold increase in AUC and 34% decrease in inter-individual variation from the reference formulation. CONCLUSION The new dosage form UniORV is a promising approach to improve the dissolution, amorphous stability, and biopharmaceutical properties of TAC, which is a poorly water-soluble drug.Little is known about how engagement with healthcare providers mediates the relationship between psychosocial factors (anxiety, depression, stigma
Like
Comment
Share
